AJP - GI AJP citation statistics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Gastrointest Liver Physiol 264: G36-G44, 1993;
0193-1857/93 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamazaki, M.
Right arrow Articles by Sugiyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamazaki, M.
Right arrow Articles by Sugiyama, Y.

AJP - Gastrointestinal and Liver Physiology, Vol 264, Issue 1 36-G44, Copyright © 1993 by American Physiological Society

ARTICLES

Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver

M. Yamazaki, H. Suzuki, M. Hanano, T. Tokui, T. Komai and Y. Sugiyama
Faculty of Pharmaceutical Sciences, University of Tokyo, Japan.

To examine whether the relatively selective inhibition of hepatic cholesterol synthesis by the hydrophilic 3-hydroxyl-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor pravastatin in vivo may be due to the existence of a specific uptake mechanism in the liver, the uptake by isolated rat hepatocytes was investigated. The uptake was composed of a saturable component [Michaelis constant (Km) 29 microM, maximal uptake rate 546 pmol.min-1.mg-1] and nonspecific diffusion (nonspecific uptake clearance 1.6 microliters.min-1.mg-1), inhibited by hypothermia, metabolic inhibitors, sulfhydryl-modifying reagents, and inhibitor of anion exchanger, whereas replacement of Na+ by choline+ or Cl- by gluconate- did not alter the uptake. Competitive inhibition was observed by a more highly lipophilic HMG-CoA reductase inhibitor simvastatin (open acid form), dibromosulfophthalein, cholate, and taurocholate. Pravastatin inhibited Na(+)-independent taurocholate uptake with an inhibition constant comparable with the Km value of pravastatin itself. Furthermore, the hepatic permeability clearance in vivo obtained with intact rats was comparable with that in vitro, indicating that the carrier-mediated active transport system we demonstrated in vitro is responsible for the hepatic uptake in vivo. These findings demonstrated that the hepatic uptake of pravastatin occurs via a carrier-mediated active transport mechanism utilizing the so-called multispecific anion transporter, which is common with the Na(+)-independent bile acid uptake system, and that this is one of the mechanisms for its selective inhibition of hepatic cholesterol synthesis in vivo.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
K. Abe, A. S. Bridges, W. Yue, and K. L. R. Brouwer
In Vitro Biliary Clearance of Angiotensin II Receptor Blockers and 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors in Sandwich-Cultured Rat Hepatocytes: Comparison with in Vivo Biliary Clearance
J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 983 - 990.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K.-i. Nezasa, K. Higaki, T. Matsumura, K. Inazawa, H. Hasegawa, M. Nakano, and M. Koike
Liver-Specific Distribution of Rosuvastatin in Rats: Comparison with Pravastatin and Simvastatin
Drug Metab. Dispos., November 1, 2002; 30(11): 1158 - 1163.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
B. Lindenthal, T. A. Aldaghlas, A. L. Holleran, T. Sudhop, H. K. Berthold, K. von Bergmann, and J. K. Kelleher
Isotopomer spectral analysis of intermediates of cholesterol synthesis in human subjects and hepatic cells
Am J Physiol Endocrinol Metab, June 1, 2002; 282(6): E1222 - E1230.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Y. Kawabata, S. Furuta, Y. Shinozaki, T. Kurimoto, and R. Nishigaki
Carrier-Mediated Active Transport of a Novel Thromboxane A2 Receptor Antagonist [2-(4-Chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335) into Rat Liver
Drug Metab. Dispos., May 1, 2002; 30(5): 498 - 504.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Nakai, R. Nakagomi, Y. Furuta, T. Tokui, T. Abe, T. Ikeda, and K. Nishimura
Human Liver-Specific Organic Anion Transporter, LST-1, Mediates Uptake of Pravastatin by Human Hepatocytes
J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 861 - 867.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Kouzuki, H. Suzuki, B. Stieger, P. J. Meier, and Y. Sugiyama
Characterization of the Transport Properties of Organic Anion Transporting Polypeptide 1 (oatp1) and Na+/Taurocholate Cotransporting Polypeptide (Ntcp): Comparative Studies on the Inhibitory Effect of their Possible Substrates in Hepatocytes and cDNA-Transfected COS-7 Cells
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 505 - 511.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
B. Hsiang, Y. Zhu, Z. Wang, Y. Wu, V. Sasseville, W.-P. Yang, and T. G. Kirchgessner
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2). IDENTIFICATION OF A LIVER-SPECIFIC HUMAN ORGANIC ANION TRANSPORTING POLYPEPTIDE AND IDENTIFICATION OF RAT AND HUMAN HYDROXYMETHYLGLUTARYL-CoA REDUCTASE INHIBITOR TRANSPORTERS
J. Biol. Chem., December 24, 1999; 274(52): 37161 - 37168.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Akhteruzzaman, Y. Kato, H. Kouzuki, H. Suzuki, A. Hisaka, B. Stieger, P. J. Meier, and Y. Sugiyama
Carrier-Mediated Hepatic Uptake of Peptidic Endothelin Antagonists in Rats
J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1107 - 1115.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
E. Fuse, H. Tanii, K. Takai, K. Asanome, N. Kurata, H. Kobayashi, T. Kuwabara, S. Kobayashi, and Y. Sugiyama
Altered Pharmacokinetics of a Novel Anticancer Drug, UCN-01, Caused by Specific High Affinity Binding to {{alpha}}1-Acid Glycoprotein in Humans
Cancer Res., March 1, 1999; 59(5): 1054 - 1060.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Kato, S. Akhteruzzaman, A. Hisaka, and Y. Sugiyama
Hepatobiliary Transport Governs Overall Elimination of Peptidic Endothelin Antagonists in Rats
J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 568 - 574.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Kouzuki, H. Suzuki, K. Ito, R. Ohashi, and Y. Sugiyama
Contribution of Organic Anion Transporting Polypeptide to Uptake of Its Possible Substrates into Rat Hepatocytes
J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 627 - 634.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Ishizuka, K. Konno, H. Naganuma, K. Nishimura, H. Kouzuki, H. Suzuki, B. Stieger, P. J. Meier, and Y. Sugiyama
Transport of Temocaprilat into Rat Hepatocytes: Role of Organic Anion Transporting Polypeptide
J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 37 - 42.
[Abstract] [Full Text]

Home page
 Pharmacol. Rev.Home page
K. Ito, T. Iwatsubo, S. Kanamitsu, K. Ueda, H. Suzuki, and Y. Sugiyama
Prediction of Pharmacokinetic Alterations Caused by Drug-Drug Interactions: Metabolic Interaction in the Liver
Pharmacol. Rev., September 1, 1998; 50(3): 387 - 412.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Imawaka and Y. Sugiyama
Kinetic Study of the Hepatobiliary Transport of a New Prostaglandin Receptor Agonist
J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 949 - 957.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Kusuhara, H. Suzuki, T. Terasaki, A. Kakee, M. Lemaire, and Y. Sugiyama
P-Glycoprotein Mediates the Efflux of Quinidine across the Blood-Brain Barrier
J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 574 - 580.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
M. Yamazaki, S. Akiyama, K. Ni'inuma, R. Nishigaki, and Y. Sugiyama
Biliary Excretion of Pravastatin in Rats: Contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (CMOAT)
Drug Metab. Dispos., October 1, 1997; 25(10): 1123 - 1129.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
M. Katashima, K. Yamamoto, K. Haraguchi, Y. Tokuma, T. Hata, Y. Sawada, and T. Iga
Tissue Distribution Kinetics of a New Nonsteroidal 5alpha -Reductase Inhibitor, 4-[3-[3-[Bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol1-yl]-butyric Acid, in Rats
Drug Metab. Dispos., September 1, 1997; 25(9): 1051 - 1058.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Sasabe, T. Terasaki, A. Tsuji, and Y. Sugiyama
Carrier-Mediated Hepatic Uptake of Quinolone Antibiotics in the Rat
J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 162 - 171.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
T. Yamada, K. Niinuma, M. Lemaire, T. Terasaki, and Y. Sugiyama
CARRIER-MEDIATED HEPATIC UPTAKE OF THE CATIONIC CYCLOPEPTIDE, OCTREOTIDE, IN RATS. Comparison between In Vivo and In Vitro
Drug Metab. Dispos., May 1, 1997; 25(5): 536 - 543.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
O. Takenaka, T. Horie, H. Suzuki, and Y. Sugiyama
Carrier-Mediated Active Transport of the Glucuronide and Sulfate of 6-Hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) into Rat Liver: Quantitative Comparison of Permeability in Isolated Hepatocytes, Perfused Liver and Liver in Vivo
J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 948 - 958.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online